Mehran Taherian1, Huamin Wang2. 1. Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
BACKGROUND AND OBJECTIVE: Preoperative neoadjuvant therapy (NAT) is increasingly used in the treatment of patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC). Because NAT often induces heterogeneous tumor response and extensive fibrosis both in tumor and adjacent pancreatic tissue, pathologic assessment of posttherapy pancreatectomy specimens is challenging. A limited number of studies examined the optimal grossing and sampling methods, tumor response grading (TRG), and the prognostic value of posttherapy tumor (ypT) and lymph node (ypN) stages of treated PDAC patients. In this review, we will provide an overview of the current status and critical issues in pathologic evaluation of PDAC resected after NAT. METHODS: In PubMed, Google Scholar and Web of Science, we reviewed existing English literature (published up to December 2021) highlighting the most recent ones using electronic databases and authors' experience to outline the challenging aspects and new perspectives on pathologic assessment of the treated PDAC. KEY CONTENT AND FINDINGS: The recent recommendations from the Pancreatobiliary Pathology Society (PBPS) provide the much-needed guidelines for systematic and standardized pathologic evaluation and reporting of treated PDAC for optimal patient care. For treated PDAC, tumor size measured by gross and radiology is not reliable. Histologic validation of tumor size on consecutive mapping sections is recommended for accurate ypT stage. A tumor size of 1.0 cm seems to be a better cutoff for ypT2 for treated PDACs. The published data suggested that the MD Anderson Cancer Center (MDA) TRG system is easy to use, has a better interobserver agreement and better correlation with patient prognosis compared to the College of American Pathologists (CAP) and Evans grading systems and may be used as an alternative TRG system for the CAP cancer protocol. CONCLUSIONS: Systemic and standardized grossing and sampling are essential for accurate pathologic evaluation and reporting for optimal care of PDAC patients who received NAT. Future studies on optimal sampling and integration of histopathology with artificial intelligence (AI), molecular and immunohistochemical markers are needed for better and personalized care of treated PDAC patients.
BACKGROUND AND OBJECTIVE: Preoperative neoadjuvant therapy (NAT) is increasingly used in the treatment of patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC). Because NAT often induces heterogeneous tumor response and extensive fibrosis both in tumor and adjacent pancreatic tissue, pathologic assessment of posttherapy pancreatectomy specimens is challenging. A limited number of studies examined the optimal grossing and sampling methods, tumor response grading (TRG), and the prognostic value of posttherapy tumor (ypT) and lymph node (ypN) stages of treated PDAC patients. In this review, we will provide an overview of the current status and critical issues in pathologic evaluation of PDAC resected after NAT. METHODS: In PubMed, Google Scholar and Web of Science, we reviewed existing English literature (published up to December 2021) highlighting the most recent ones using electronic databases and authors' experience to outline the challenging aspects and new perspectives on pathologic assessment of the treated PDAC. KEY CONTENT AND FINDINGS: The recent recommendations from the Pancreatobiliary Pathology Society (PBPS) provide the much-needed guidelines for systematic and standardized pathologic evaluation and reporting of treated PDAC for optimal patient care. For treated PDAC, tumor size measured by gross and radiology is not reliable. Histologic validation of tumor size on consecutive mapping sections is recommended for accurate ypT stage. A tumor size of 1.0 cm seems to be a better cutoff for ypT2 for treated PDACs. The published data suggested that the MD Anderson Cancer Center (MDA) TRG system is easy to use, has a better interobserver agreement and better correlation with patient prognosis compared to the College of American Pathologists (CAP) and Evans grading systems and may be used as an alternative TRG system for the CAP cancer protocol. CONCLUSIONS: Systemic and standardized grossing and sampling are essential for accurate pathologic evaluation and reporting for optimal care of PDAC patients who received NAT. Future studies on optimal sampling and integration of histopathology with artificial intelligence (AI), molecular and immunohistochemical markers are needed for better and personalized care of treated PDAC patients.
Authors: Laurice K Fischer; Matthew H Katz; Sun M Lee; Li Liu; Hua Wang; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Anirban Maitra; Christina L Roland; Jason B Fleming; Jeannelyn Estrella; Asif Rashid; Huamin Wang Journal: Histopathology Date: 2015-06-19 Impact factor: 5.087
Authors: Roheena Z Panni; Ivan Gonzalez; Christopher P Hartley; Gregory A Williams; Jingxia Liu; William G Hawkins; Deyali Chatterjee Journal: Am J Surg Pathol Date: 2018-11 Impact factor: 6.394
Authors: Li Liu; Matthew H Katz; Sun M Lee; Laurice K Fischer; Laura Prakash; Nathan Parker; Hua Wang; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Peter W Pisters; Anirban Maitra; Jason B Fleming; Jeannelyn Estrella; Asif Rashid; Huamin Wang Journal: Am J Surg Pathol Date: 2015-10 Impact factor: 6.394
Authors: Caroline Verbeke; Fleur Webster; Lodewijk Brosens; Fiona Campbell; Marco Del Chiaro; Irene Esposito; Roger M Feakins; Noriyoshi Fukushima; Anthony J Gill; Sanjay Kakar; James G Kench; Alyssa M Krasinskas; Jean-Luc van Laethem; David F Schaeffer; Kay Washington Journal: Histopathology Date: 2021-09-22 Impact factor: 5.087
Authors: Boris V Janssen; Faik Tutucu; Stijn van Roessel; Volkan Adsay; Olca Basturk; Fiona Campbell; Claudio Doglioni; Irene Esposito; Roger Feakins; Noriyoshi Fukushima; Anthony J Gill; Ralph H Hruban; Jeffrey Kaplan; Bas Groot Koerkamp; Seung-Mo Hong; Alyssa Krasinskas; Claudio Luchini; Johan Offerhaus; Arantza Fariña Sarasqueta; Chanjuan Shi; Aatur Singhi; Thomas F Stoop; Eline C Soer; Elizabeth Thompson; Geertjan van Tienhoven; Marie-Louise F Velthuysen; Johanna W Wilmink; Marc G Besselink; Lodewijk A A Brosens; Huamin Wang; Caroline S Verbeke; Joanne Verheij Journal: Mod Pathol Date: 2020-10-12 Impact factor: 7.842